Storia in 2 fonti

Moonwalk reloads with $70M and new RNAi prospects for obesity

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo4 g fa

Moonwalk reloads with $70M and new RNAi prospects for obesity

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

originale

endpoints.news3 g fa

Moonwalk raises $70M to test siRNA treatment for obesity

Moonwalk Biosciences raises $70M Series B to push MW-101, an siRNA obesity drug aimed at fat tissue, toward a 2027 trial start.

Leggi questa versione → originale

Timeline cronologica

martedì 8 settembre 2026·biopharmadive.com
Moonwalk reloads with $70M and new RNAi prospects for obesity
The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.
martedì 8 settembre 2026·endpoints.news
Moonwalk raises $70M to test siRNA treatment for obesity
Moonwalk Biosciences raises $70M Series B to push MW-101, an siRNA obesity drug aimed at fat tissue, toward a 2027 trial start.